Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was…
In Conversation
It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry,…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI…
